Pathologic material was reviewed and survival data were obtained on 182 of the endometrial cancer patients reported in our previous study (1975) to compare histopathologic characteristics and clinical behavior (survival) between endometrial adenocarcinoma in estrogen users and nonusers. In addition, relative risk estimates of estrogen-associated endometrial carcinoma were calculated from review results. This work identifies estrogen users as having a significantly higher frequency of low-grade tumor with an associated improved survival even when numerous clinical parameters are taken into account. Other histologic or clinical characteristics of the disease did not relate significantly to estrogen use after taking account of histologic grade. The marked increase in endometrial cancer risk among estrogen users was confirmed by the pathology review (relative risk 6.44) and is evident even when attention is restricted to diesease that has invaded the myometrium (relative risk 6.09).

Keywords:
Endometrial cancer, Estrogen, Survival, Risk, Histopathology
This content is only available via PDF.
© 1981 S. Karger AG, Basel
1981
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.